Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals

Summary

Phase 1b, randomized, open-label, study to evaluate the safety, tolerability, and immunogenicity of RVM-V001 only, RVM-V002 only, or RVM V001 + RVM V002 (Co administered as Separate Injections) in healthy adults. The study will be conducted at one site in Singapore.

Timeline

Start

2023-03-22

Primary completion

2023-09-21

Completion

2023-09-21

Outcome

Outcome not reported

Stopped: “Changes in COVID-19 pandemic landscape”

Drugs

Indications